Anaptysbio (ANAB) Net Equity Issued and Repurchased (2017 - 2026)
Anaptysbio (ANAB) posted Net Equity Issued and Repurchased of $14.0 million for Q1 2026, up 14.81% on a QoQ basis from $12.2 million in Q4 2025, and up 4734.83% year-over-year from $290000.0 in Q1 2025.
Anaptysbio (ANAB) Net Equity Issued and Repurchased (2017 - 2026) Analysis & Trends
Anaptysbio's Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $14.0 million for Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 4734.83% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 million (up 962.31% YoY) and the FY2025 annual result came in at $14.3 million, up 120.32% from the prior year.
- Net Equity Issued and Repurchased was $14.0 million for Q1 2026 at Anaptysbio, up from $12.2 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $14.0 million in Q1 2026 and bottomed at $160000.0 in Q3 2023.
- A 5-year average of $2.8 million and a median of $922000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased tumbled 94.07% — and 2026, when it surged 4734.83%.
- Anaptysbio's Net Equity Issued and Repurchased stood at $3.4 million in 2022, then sank by 92.28% to $264000.0 in 2023, then jumped by 110.23% to $555000.0 in 2024, then surged by 2100.36% to $12.2 million in 2025, then climbed by 14.81% to $14.0 million in 2026.
- Business Quant data shows ANAB's Net Equity Issued and Repurchased at $14.0 million in Q1 2026, $12.2 million in Q4 2025, and $336000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Anaptysbio | 1.58 Bn | 1.29 Bn | - | 14.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.02 Mn |
| Mar 31, 2026 | 14.02 Mn |
| Dec 31, 2025 | 12.21 Mn |
| Dec 31, 2025 | 12.21 Mn |
| Sep 30, 2025 | 336,000.00 |
| Sep 30, 2025 | 336,000.00 |
| Jun 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 290,000.00 |
| Mar 31, 2025 | 290,000.00 |
| Dec 31, 2024 | 555,000.00 |
| Dec 31, 2024 | 555,000.00 |
| Jun 30, 2024 | 979,000.00 |
| Jun 30, 2024 | 979,000.00 |
| Mar 31, 2024 | 811,000.00 |
| Mar 31, 2024 | 811,000.00 |
| Dec 31, 2023 | 264,000.00 |
| Dec 31, 2023 | 264,000.00 |
| Sep 30, 2023 | 160,000.00 |
| Sep 30, 2023 | 160,000.00 |